Stock Events

Stock Events

Bright Minds Biosciences 

$75.18
69
+$5.62+8.08% Today

Statistics

Day High
75.18
Day Low
75.18
52W High
-
52W Low
-
Volume
5
Avg. Volume
-
Mkt Cap
585.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2025
Q4 2025
Next
-0.89
-0.74
-0.59
-0.44
Expected EPS
-0.89118476564
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-17.59MNet Income

Analyst Ratings

$124.00Average Price Target
The highest estimate is 147.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DRUG.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals has a strong portfolio in neuroscience, including treatments for psychiatric disorders, overlapping with Bright Minds' focus.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Acadia Pharmaceuticals develops drugs for central nervous system disorders, directly competing with Bright Minds in the psychiatric and neurological treatment market.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes focuses on central nervous system diseases, including schizophrenia and depression, competing in the same therapeutic areas as Bright Minds.
BridgeBio Pharma
BBIO
Mkt Cap12.07B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs, some of which involve neurological conditions, making them a competitor.
Corbus Pharmaceuticals
CRBP
Mkt Cap148.9M
Corbus Pharmaceuticals works on treatments for inflammatory and fibrotic diseases with potential applications in neuropsychiatric disorders.
Neurocrine Biosciences
NBIX
Mkt Cap14.28B
Neurocrine Biosciences specializes in neurologic, psychiatric, and endocrine-related diseases, directly competing in Bright Minds' market.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including treatments for neurological disorders, making them a competitor in the broader neuropharmaceutical field.

About

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Ian McDonald
Country
CA
ISIN
CA10919W4056

Listings

XNAS
US
DRUG
CN
CA
DRUG.CN
BOATS
BOATS
DRUG.BOATS

0 Comments

Share your thoughts

FAQ

What is Bright Minds Biosciences stock price today?▼
The current price of DRUG.BOATS is $75.18 USD — it has increased by +8.08% in the past 24 hours. Watch Bright Minds Biosciences stock price performance more closely on the chart.
What is Bright Minds Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bright Minds Biosciences stocks are traded under the ticker DRUG.BOATS.
What is Bright Minds Biosciences market cap?▼
Today Bright Minds Biosciences has the market capitalization of 585.43M
When is the next Bright Minds Biosciences earnings date?▼
Bright Minds Biosciences is going to release the next earnings report on May 14, 2026.
What were Bright Minds Biosciences earnings last quarter?▼
DRUG.BOATS earnings for the last quarter are -0.71 USD per share, whereas the estimation was -0.86 USD resulting in a +18.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bright Minds Biosciences revenue for the last year?▼
Bright Minds Biosciences revenue for the last year amounts to 0 USD.
What is Bright Minds Biosciences net income for the last year?▼
DRUG.BOATS net income for the last year is -17.59M USD.
In which sector is Bright Minds Biosciences located?▼
Bright Minds Biosciences operates in the Health Care sector.
When did Bright Minds Biosciences complete a stock split?▼
Bright Minds Biosciences has not had any recent stock splits.
Where is Bright Minds Biosciences headquartered?▼
Bright Minds Biosciences is headquartered in New York, CA.